Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 195 participants.
Also called NCT07271186
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 195 participants
- Sponsor
- Registry
-
NCT07271186 -
2026-527519-41-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07271186. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-09 (actual); primary completion 2028-10-13 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
- Acronym
- ANCHOR-POC
- Condition
- Diabetic Kidney Disease (DKD)
- Intervention (Drug)
- ALN-ANG3
- Intervention (Drug)
- Evinacumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07271186- Content hash
89f5b38bab61875aa49af5b9ad916ca53e0cd3a5be9da8e498010386c292bbda